What do we already know about this topic?
The MINIMED Advanced Hybrid Closed-Loop (AHCL) system is an automated system for insulin delivery in persons with type 1 diabetes (T1D).
It is designed to maximize the glucose time in range (TIR) of 70-180 mg/dL.
The system auto basal adjusts every 5 minutes to target 100 or 120 mg/dL.
How was this study conducted?
The AHCL study investigated the use of the system.
The trial enrolled 157 individuals with T1D who were on pump therapy with or without continuous glucose monitoring.
Descriptive glycemic endpoints were used.
After the run-in patients were allocated to a glucose set point of 100 or 120 mg/dL for 45 days, and then crossed over to either 100 or 120 mg/dL.